Avosentan: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9912992 |
| CHEMBL ID | 3989834 |
| SCHEMBL ID | 2742679 |
| MeSH ID | M0534901 |
| Synonym |
|---|
| HY-15195 |
| ro 67-0565; spp-301 |
| AVOSENTAN,CAS:290815-26-8 |
| avosentan |
| 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide |
| spp301 |
| L001646 |
| FT-0662342 |
| spp 301 |
| 2-pyridinesulfonamide, n-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl- |
| ro 67-0565 |
| l94ksx715k , |
| 290815-26-8 |
| avosentan [inn] |
| unii-l94ksx715k |
| CS-0625 |
| n-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide |
| gtpl8260 |
| spp-301 |
| n-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide |
| ro-67-0565 |
| 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide |
| YBWLTKFZAOSWSM-UHFFFAOYSA-N |
| 5-methyl-pyridine-2-sulfonic acid[6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide |
| SCHEMBL2742679 |
| AC-33590 |
| DTXSID30183330 |
| NCGC00379058-01 |
| ro670565 |
| CHEMBL3989834 |
| n-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide |
| Q27074636 |
| BCP28417 |
| 2-pyridinesulfonamide, n-[6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl- |
| HMS3741G07 |
| F84811 |
| MS-28915 |
| bdbm50532577 |
Avosentan (SPP301) is a potent and highly selective ETA receptor blocker. It is clinically investigated in diabetic nephropathy.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Avosentan is a potent, selective endothelin A receptor blocker. " | ( Influence of food intake on the pharmacokinetics of avosentan in man. Dieterle, W; Hengelage, T, 2008) | 2.04 |
| "Avosentan is a potent, selective endothelin A receptor blocker. " | ( Absolute bioavailability and pharmacokinetics of avosentan in man. Dieterle, W; Hengelage, T, 2009) | 2.05 |
| "Avosentan (SPP301) is a potent and highly selective ETA receptor blocker and is clinically investigated in diabetic nephropathy. " | ( Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. Dieterle, W; Mann, J, 2006) | 2.15 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Avosentan has a strong inhibitory effect on the endothelin-1-induced contractions. " | ( Effect of avosentan (SPP-301) in porcine ciliary arteries. Flammer, J; Konieczka, K; Meyer, P; Mozaffarieh, M; Neutzner, A; Schoetzau, A, 2011) | 2.21 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In avosentan-treated patients, body weight increase, but not hemoglobin decrease, was associated with CHF development, indicating that close body weight monitoring could provide an early signal of CHF development in future trials with endothelin receptor antagonists." | ( Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. de Zeeuw, D; Green, D; Hoekman, J; Lambers Heerspink, HJ; Mann, JF; Viberti, G, 2014) | 1.02 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Cmax and AUC values increased linearly with doses up to 100 mg." | ( Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. Dieterle, W; Kutz, K; Mann, J, 2004) | 0.32 |
| " The apparent terminal half-life of SPP301 and the metabolite was in the range of 7-10 hours after single and repeated doses." | ( Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man. Dieterle, W; Kutz, K; Mann, J, 2005) | 0.33 |
| " The maximum plasma concentration (Cmax) of avosentan and its metabolite was increased by food intake, and their apparent terminal half-life (t1/2) was shortened." | ( Influence of food intake on the pharmacokinetics of avosentan in man. Dieterle, W; Hengelage, T, 2008) | 0.86 |
The absolute bioavailability of avosentan film-coated tablets is high, i.e. administration of single doses was determined.
| Excerpt | Reference | Relevance |
|---|---|---|
| " administration of single doses of avosentan and its absolute bioavailability was determined." | ( Absolute bioavailability and pharmacokinetics of avosentan in man. Dieterle, W; Hengelage, T, 2009) | 0.88 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Moving forward, such studies must be conducted with careful patient selection and attention to dosing in order to minimize adverse side effects." | ( Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Kohan, DE; Pollock, DM, 2013) | 0.39 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 26.8370 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 26.8370 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 26.8370 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 26.8370 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 26.8370 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | IC50 (µMol) | 0.9000 | 0.0001 | 0.6565 | 9.8000 | AID1626368; AID1626373 |
| Endothelin-1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.0023 | 0.0000 | 0.7647 | 9.9000 | AID1626371; AID1626372 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1626371 | Displacement of 125I-ET1 from ETA receptor (unknown origin) expressed in CHO cells | 2016 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15 | From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. |
| AID1626368 | Displacement of radioligand from ETB receptor in human placenta cell membranes | 2016 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15 | From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. |
| AID1626372 | Antagonist activity at ETA receptor (unknown origin) in presence of ET1 | 2016 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15 | From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. |
| AID1626373 | Antagonist activity at ETB receptor (unknown origin) in presence of ET1 | 2016 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15 | From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 17 (58.62) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (34.48%) | 5.53% |
| Reviews | 8 (27.59%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (37.93%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||